CEPI is a partnership between public, private, philanthropic, and civil organisations to develop vaccines against future epidemics and pandemics.
The agreement, worth $4.3 million, is the first to be announced as part of CEPI’s call in January 2022 for proposals aimed at improving thermostability of a variety of new vaccine platforms, so as to improve equitable access.
Representing a significant milestone for Vaxxas, it builds on its pre-clinical portfolio into mRNA vaccines, with the potential to expand the company’s vaccine technology pipeline across a number of diseases, including COVID-19.
